Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × COVID-19 × cilgavimab and tixagevimab drug combination × Clear all

Phase

Status

Withdrawn 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1 COVID-19 1

Interventions

Standard of Care 2 tocilizumab 1 remdesivir 1 palbociclib 1 ogalvibart 1 crexavibart 1 cilgavimab and tixagevimab drug combination 1 Practice Guidelines as Topic 1 Immunoglobulin G 1 Hydroxychloroquine 1 Disulfides 1 Blood Specimen Collection 1 Azithromycin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05465876 2024-04-04

PACE-CLL

Sunnybrook Health Sciences Centre

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

COVID-19, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡